|
The history of AIDS (Acquired Immunodeficiency Syndrome), with timelines, photos, and links to resources on the Internet. Endeavoring to raise public awareness through understanding.
|
|
The History of AIDS: Timeline of the History of HIV/AIDS: 1991 - 1992 1991 On May 30, FDA authorized pre-approval distribution of dideoxycytidine (ddC) under a treatment IND protocol for the treatment of patients with AIDS or advanced AIDS Related Complex who cannot be maintained on zidovudine (AZT). On September 27, FDA approved Foscavir (foscarnet) for use in the treatment of cytomegalovirus retinal infections in persons with AIDS. On October 9, FDA approved Videx (didanosine, ddI) for the treatment of adult and pediatric patients (over 6 months of age) with advanced HIV infection. This approval involved the historic joint review between officials at FDA and our regulatory counterparts in Canada. The first combination test to detect HIV-1 and HIV-2 antibodies was licensed. On November 8, FDA authorized pre-approval distribution of atovaquone under a treatment IND protocol to patients who have Pneumocystis carinii pneumonia and cannot tolerate trimethoprim sulfamethoxazole, a standard treatment for this condition. 1992 On March 6, FDA authorized pre-approval distribution of rifabutin under a treatment IND protocol for preventing or delaying the onset of Mycobacterium avium complex, a severe infection that often afflicts AIDS patients. On May 27, FDA licensed SUDS HIV-1, a ten minute diagnostic test kit which can be used by health professionals to detect the presence of HIV-1. On June 19, FDA approved zalcitabine, commonly known as ddC, for use in combination with zidovudine (AZT) as a treatment option for adult patients with advanced HIV infection who show signs of clinical or immunological deterioration. Zalcitabine, manufactured and distributed by Hoffmann-La Roche under the trade name Hivid, was the first drug approved under the principles and procedures of FDA's proposed accelerated drug approval policy. On September 11, FDA approved Sporanox (itraconazole) for the treatment of blastomycosis and histoplasmosis in immunocompromised and non-immunocompromised patients. On September 25, FDA approved new labeling for Videx (didanosine, ddI). The data demonstrated that the lower dose of ddI is equally efficacious and associated with lower rates of toxicity, especially pancreatitis. On October 5, d4T (stavudine) was the first drug made available for expanded investigational use under the parallel track policy. On October 8, FDA approved new labeling for nonprescription drugs for vaginal candidiasis. The revised labeling advised women that frequent or persistent cases of vaginal fungal infections may sometimes be an early warning of HIV infection. On November 25, FDA approved Mepron (atovaquone) for the treatment of mild to moderate PCP in patients who are intolerant of trimethoprim-sulfamethoxazole, the standard therapy. On December 22, FDA approved Marinol (dronabinol) for a new indication for the treatment of anorexia and weight loss associated with AIDS. On December 23, FDA approved Mycobutin (rifabutin) for prophylaxis against Mycobacterium avium complex, a severe infection that often afflicts AIDS patients. 1981 - 1987 ...Last ||| Next... 1993 - 1994 |